The interaction among insulin resistance, liver fibrosis and early virological response in Egyptian patients with chronic hepatitis C

Canadian Journal of Gastroenterology

Volumn 26, Issue 6, 2012, Pages 325-329

  Ziada, Dina H ^a   El Saadany, Sherif ^a   Enaba, Mohamed ^a   Ghazy, Medhat ^a   Hasan, Azza ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

HCV; HCV therapy response; HOMA IR; Insulin resistance; Liver fibrosis

Indexed keywords

INSULIN; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGYLATED INTERFERON ALPHA 2A; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EGYPT; FEMALE; HEPATITIS C; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL;

EID: 84862616045     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2012/291457     Document Type: Article

References (37)

1. Flamm SL. Chronic hepatitis C virus infection. JAMA 2003;289:2413-7.
2. Mazzaro C, Panarello G, Tesio F, et al. Hepatitis C virus risk: A hepatitis C virus-related syndrome. J Intern Med 2000;247:535-45.
3. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003;125:1695-704.
4. Svegliati-Baroni G, Bugianesi E, et al. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in nonalcoholic fatty liver disease. Gut 2007;56:1296-301.
5. Dai CY, Chuang WL, Ho CK, et al. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: A community-based study. J Hepatol 2008;49:9-16.
6. Taura N, Ichikawa T, Hamasaki K, et al. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. Am J Gastroenterol 2006;101:2752-9.
7. Petit JM, Bour JB, Galland-Jos C, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001;35:279-83.
8. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: Direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004;126:840-8.
9. Masini M, Campani D, Boggi U, et al. Hepatitis C virus infection and human pancreatic b-cell dysfunction. Diabetes Care 2005;28:940-1.
10. Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through upregulation of suppressor of cytokine signaling 3. Am J Pathol 2004;165:1499-508.
11. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 2002;277:1531-7.
12. Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.
13. Romero-Gomez M, Del MV, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-41
14. Grasso A, Malfatti F, De Leo P, et al. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol 2009;51:984-90.
15. Narita R, Abe S, Kihara Y, Akiyama T, Tabarau A, Otsuki M. Insulin resistance and insulin secretion in chronic hepatitis C virus infection. J Hepatol 2004;41:132-8.
16. Knobler H, Zhornicky T, Sandler A, Haran N, Ashur Y, Schattner A. Tumor necrosis factor-a-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol 2003;98:2751-6.
17. Conjeevaram HS, Kleiner DE, Everhart JE, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007;45:80-7.
18. Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011;31(Suppl 2):61-80.
19. Hadziyannis SJ, Sette Jr H, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
20. Ishak KG. Chronic hepatitis: Morphology and nomenclature. Mod Pathol 1994;7:690-713.
21. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999;29:328-33.
22. Sumie S, Kawaguchi T, Komuta M, et al. Significance of glucose intolerance and SHIP2 expression in hepatocellular carcinoma patients with HCV infection. Oncol Rep 2007;18:545-52.
23. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460-8.
24. Fartoux L, Poujol-Robert A, Guéchot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005;54:1003-8.
25. Cua IH, Hui JM, Kench JG, George J. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 2008;48:723-31
26. Halfon P, Pénaranda G, Carrat F. Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients. Aliment Pharmacol Ther 2009;30:61-70. Epub March 9, 2009.
27. Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: A potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001;34:738-44.
28. Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008;48:28-34. Epub October 1, 2007.
29. Fartoux L, Serfaty L, Lefevre G, et al. Steatosis, oxidative stress and fibrosis in chronic hepatitis C. Hepatology 2003;38:363A.
30. Day CP, James OF. Steatohepatitis: A tale of two "hits"? Gastroenterology 1998;114:842-5.
31. Lerat H, Honda M, Beard MR, et al. Steatosis and liver cancer in transgenic mice expressing the structural and non-structural proteins of hepatitis C virus. Gastroenterology 2002;122:352-65.
32. Letteron P, Fromenty B, Terris B, et al. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996;24:200-8.
33. Merchante N, Macías J, Palacios RB, et al. Prevalence of non-significant liver fibrosis and rate of fibrosis progression in HIV/hepatitis C virus- co-infected patients: Still a role for liver biopsy? AIDS 2004;18:1746-8.
34. Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C. New Microbiol 2005;28:13-21.
35. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 2007;22:832-6.
36. Grasso A, Malfatti F, De Leo P, et al. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol 2009;51:984-90. Epub July 23, 2009.
37. Khattab M, Emad M, Abdelaleem A. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int 2010;30:447-54. Epub November 16, 2009.